Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
Rhea-AI Summary
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, QNTM declined 11.65%, reflecting a significant negative market reaction. Argus tracked a peak move of +12.4% during that session. Argus tracked a trough of -9.8% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $38M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers like MNOV (-1.31%), ABVC (-0.44%), APLT (-1.77%), DTIL (-2.19%) and PMVP (-0.79%) were down, and momentum scanner flagged MAIA at -4.17%, suggesting broader sector softness rather than a QNTM-specific upside move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Private placement | Neutral | -0.2% | Small private placement, related-party participation and ATM termination update. |
| Dec 01 | Media coverage lawsuit | Neutral | -11.7% | Final W5 segment on alleged USD $700M stock manipulation case. |
| Nov 28 | Media coverage lawsuit | Neutral | -15.0% | Repeat release of W5 Part 2 on alleged stock spoofing. |
| Nov 27 | Media coverage lawsuit | Neutral | -15.0% | Initial W5 Part 2 airing on alleged market manipulation. |
| Nov 26 | Media coverage lawsuit | Neutral | +41.9% | Announcement that Quantum’s USD $700M lawsuit is focus of W5 series. |
Recent W5-related news on the alleged stock manipulation lawsuit coincided with large swings, including a sharp gain followed by multiple double-digit declines around subsequent segments.
Over late Nov–Dec 2025, Quantum BioPharma’s news flow centered on its alleged USD $700 million stock market manipulation lawsuit and the W5 three-part investigative series. The initial W5 announcement on Nov 26 saw a 41.92% gain, while later segments on Nov 27, Nov 28, and the final piece on Dec 1 coincided with declines of -14.99%, -14.99%, and -11.65%. A small private placement and ATM termination on Dec 10 saw a modest -0.19% move.
Market Pulse Summary
The stock dropped -11.7% in the session following this news. A negative reaction despite heightened media attention would fit prior episodes where later W5 segments coincided with declines of -14.99% and -11.65% after an earlier 41.92% jump. This history suggested that initial enthusiasm around the lawsuit coverage was followed by selling pressure. With shares already far below the 52-week high, traders could reassess how much of the legal overhang and headline risk had been reflected previously.
Key Terms
stock spoofing technical
market manipulation technical
multiple sclerosis (MS) medical
AI-generated analysis. Not financial advice.
TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired the final segment, Part Three, of their three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.
Award-winning CTV News journalist and W5 investigative reporter Jon Woodward provides highlights of Part Three of the series in an article entitled, “‘Market manipulation’ cases trending up in Canada; regulator data”.
The series explores the phenomenon of “stock spoofing”, a market manipulation tactic that is illegal in Canada and the United States, and the basis of a USD
The entire series can be found here:
Part One: W5: MS research derailed by stock market spoofing: lawsuit
Part Two: W5: ’Something was wrong’: Inside a Canadian biotech firm’s fight against alleged ’stock spoofing’
Part Three: W5: ‘Market manipulation’ cases trending up in Canada: regulator data
Quantum BioPharma CEO Zeeshan Saeed commented, “Quantum BioPharma will continue to stand up for its shareholders. Stock market manipulation is a serious and damaging issue for all publicly traded companies and their shareholders. We are determined to stand up for the company and its investors, so that we can continue to advance research, and bring hope and improved treatments to those living with multiple sclerosis (MS).”
Quantum BioPharma’s Co-Executive Chair, Anthony Durkacz, added, “We encourage other companies and individuals to speak out against illegal market manipulation, including stock spoofing. Quantum BioPharma invites anyone with information concerning illegal efforts to manipulate Quantum’s stock to contact us. We are offering up to USD
For more information visit: www.quantumbiopharma.com
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
This press release contains certain "forward-looking statements" within the meaning of applicable securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “hopes”, “alleges”, “pending”, “further”, or variations of such words and phrases or statements that certain actions events or results “may”, “could”, “which”, or “will” and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements regarding: the Company’s ongoing litigation against major financial institutions; the potential outcome or judgment value; expectations regarding whistleblower submissions and related rewards; continued market integrity initiatives; future business performance and possible acquisitions.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the ability to obtain and validate whistleblower evidence; the timing and outcome of legal proceedings; resolution of ongoing litigation on favourable terms, availability and sufficiency of litigation funding; continued regulatory compliance and market stability for the Company’s operations.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the adverse outcome of legal actions; the receipt and credibility of whistleblower disclosures; changes in applicable laws and regulations; the actions of third parties involved in alleged manipulation; evolving market dynamics; the sufficiency of future litigation proceeds to fund the Company’s whistleblower reward; the continued ability to obtain sufficient litigation funding; limited future growth opportunities, and reliance on key personnel.
Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
